Bayes Pharma.ai connects questions, evidence, uncertainty, expert interpretation, and next actions across innovator development, generic development, and clinical diagnostic-to-dosing support.
The team combines pharmaceutical sciences, Bayesian modeling, machine learning, and product engineering to make complex development work easier to reason about.
Founder and architect of Bayes Pharma.ai, leading product vision, platform strategy, and engineering of science-first decision intelligence. Connects pharmaceutical sciences, Bayesian modeling, applied AI, model-to-API infrastructure, and clinical evidence workflows.
Co-Founder, Co-CEO, Chief Scientific Officer and Marketing lead of Bayes Pharma.ai. Brings extensive drug-discovery research experience across GPCR and molecular pharmacology, high-throughput and cell-based assays, molecular biology, bioanalysis, electrophysiology, biophysics, preclinical pharmacology, scientific quality, and cross-functional development.
Advises on product direction, scientific workflow design, and regulatory evidence strategy. Brings experience across clinical pharmacokinetics, PK/PD modeling, PopPK, PBPK, preclinical DMPK, medical writing, and cross-functional development decisions.
Teams often work across disconnected models, documents, dashboards, and review cycles. Bayes Pharma.ai keeps the scientific question, supporting evidence, uncertainty, and next action together — making collaboration clearer without hiding the assumptions experts need to inspect.
Start with the scientific or regulatory question, not a generic feature.
Bring models, assumptions, external intelligence, and context into one view.
Support scenario comparison and expert review instead of false certainty.
Turn decisions into reusable evidence for the next team or regulatory interaction.
Every Bayes Pharma.ai product follows the same reviewable path while preserving the methods and ownership appropriate to its domain.
Keep sources, models, documents, assumptions, and program context attached to the question they inform.
Present ranges, limitations, scenarios, and unresolved questions alongside interpretation.
Make ownership, comments, review state, and accountable judgment part of the workflow.
Preserve why a decision was made so later teams and milestones can inspect and reuse the context.
Innovator development, generic development, and patient-level clinical review share scientific foundations, but each requires its own evidence, governance, and expert workflow.
Decision intelligence from candidate discovery through clinical MIDD and submission-ready regulatory evidence.
Explore InnovatorConnected formulation, reverse engineering, scale-up, bioequivalence, quality, and ANDA readiness.
Explore GenericsConnected diagnostic workup, test intelligence, medication safety, Bayesian dosing, TDM, and patient-level review.
Explore ClinicalChoose the product path that fits your work, then evaluate Bayes Pharma.ai against the evidence, review process, and next action your team needs.